Cytosorbents Corp has amended its financial results for the third quarter of 2026, correcting several errors related to its previously reported figures. This amendment is significant as it underscores the company's commitment to transparency and accuracy in its financial reporting.

On November 19, 2026, the company filed an amendment to its earlier report, initially submitted on November 12, 2026. The amendment addresses inaccuracies in the financial results for the quarter ended September 30, 2026, particularly concerning foreign currency transaction losses, balance sheet figures, and operational expenses.

Background

Cytosorbents Corp, traded on the NASDAQ under the ticker CTSO, operates in the surgical and medical instruments and apparatus sector (SIC 3841). The company specializes in blood purification technologies aimed at treating life-threatening conditions in intensive care and cardiac surgery settings. The firm has been active in providing updates on its financial status, with recent filings including a 10-Q on the same day as this amendment.

What the Filing Says

The filing states, "The Company is filing this Amendment solely to correct certain financial information contained in the press release issued by the Company on November 12, 2026." It highlights that the revised press release corrects immaterial errors in various financial metrics, including operational expenses and revenue growth percentages.

Impact

This amendment may affect investors and stakeholders who rely on accurate financial data to make informed decisions. It also sets a precedent for other companies in the surgical and medical instruments industry, emphasizing the importance of precise financial reporting.

What's Next

The filing does not say what happens next.